Abstract | BACKGROUND:
Hearing loss is generally regarded as a rare side effect of erythromycin therapy. However, our own clinical experiences in erythromycin-treated patients led us to suspect that this complication may be more common among renal allograft recipients. The purpose of this study was to evaluate the incidence, predisposing factors, clinical characteristics, and outcomes of erythromycin-induced hearing loss among renal allograft recipients. METHODS: RESULTS: Eleven (32%) of 34 courses of intravenous erythromycin therapy resulted in hearing loss. The incidence of hearing loss was 53% (eight of 15 courses) in patients treated with 4 g of erythromycin daily compared with 16% (three of 19 courses) among those receiving 2 g/d (P = .05). In addition, courses of erythromycin were longer in those suffering auditory toxicity (9.6 +/- 4.7 days) than in nontoxic patients (5.7 +/- 3.6 days) (P < .05). Hepatic and renal function did not differ between toxic and nontoxic patients. All episodes of erythromycin-induced hearing loss were reversible. CONCLUSIONS:
|
Authors | E M Vasquez, M S Maddux, J Sanchez, R Pollak |
Journal | Archives of internal medicine
(Arch Intern Med)
Vol. 153
Issue 7
Pg. 879-82
(Apr 12 1993)
ISSN: 0003-9926 [Print] United States |
PMID | 8466379
(Publication Type: Journal Article)
|
Chemical References |
- erythromycin lactobionate
- Erythromycin
|
Topics |
- Adult
- Causality
- Erythromycin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Female
- Hearing Loss
(chemically induced)
- Humans
- Infusions, Intravenous
- Kidney Transplantation
- Male
- Middle Aged
- Pneumonia
(drug therapy)
- Retrospective Studies
- Transplantation, Homologous
|